Next, the therapeutic effect of HSA-Trx on NASH was also evaluated by administering HSA-Trx from 4 weeks after HFD feeding, corresponding to the initial phase of NASH pathology in the control group (HFD + PBS). Here, TXN is linked to metabolic dysfunction-associated steatohepatitis.